Sai Parenterals: New CS and COO appointed, prior CS resigns

Kmp ResignedManagement Changes View source PDF Explain this filing

SAIPARENT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.4%Reaction day

₹502.00

prior close

₹509.60

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+5.6% vs market

Pharmaceuticals peers, median of 172sector-0.9%+6.3% vs sector

On the reaction day the stock moved 5.6 pts more than Nifty Microcap 250 and 6.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+0.1

15m

+0.0

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.4-0.3+5.6-0.9+6.3

Next day

+4.1-1.5+5.7-1.7+5.8

-1.4-1.5+0.2-2.6+1.2

+4.4-0.2+4.6-1.5+5.9

+3.4-0.5+3.9-1.8+5.2

+0.0-3.2+3.2-3.5+3.5

+0.4-2.2+2.6-4.4+4.8

15d

-9.2-9.5+0.3-9.1-0.0

+3.1pendingpending-6.8+9.9

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

At a board meeting on 30 September 2026, Sai Parenterals accepted the resignation of Company Secretary Shivali Aggarwal for personal reasons, effective the same day. The board appointed Ashwani Singh Bisht as the new Company Secretary and Compliance Officer, a qualified CS with over 12 years of experience including 5 years in secretarial and compliance. Arvind Gannimitta, who holds a PhD in Pharmaceuticals and brings 26 years of pharma manufacturing and operations experience, was appointed as Chief Operating Officer.

Likely market impact

Smooth leadership transition in secretarial and operations roles; new COO's deep pharma expertise may support operational growth.